New drug combo aims to wipe out prostate cancer before surgery
NCT ID NCT05009290
First seen Apr 06, 2026 · Last updated May 16, 2026 · Updated 8 times
Summary
This study tested whether adding the drug SHR3680 to standard hormone therapy could improve outcomes for men with high-risk prostate cancer who were scheduled for prostate removal surgery. The trial involved 391 participants and looked at how many had no cancer left in the removed prostate and how long they lived without the cancer spreading. The study was stopped early, so final results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PATIENTS WITH HIGH-RISK LOCALIZED OR LOCALLY ADVANCED PROSTATE CANCER WHO ARE CANDIDATES FOR RADICAL PROSTATECTOMY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer center
Shanghai, Shanghai Municipality, China
Conditions
Explore the condition pages connected to this study.